Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14404923 | 1.00 | L3MBTL1 (0.40) | L3MBTL1AKR1C3CSF1RPOLBKMT2A | |
| SCHEMBL5650093 | 1.00 | L3MBTL1 (0.40) | L3MBTL1AKR1C3CSF1RPOLBKMT2A | |
| SCHEMBL14405083 | 0.81 | CSF1R (0.39) | L3MBTL1AKR1C3CSF1RSIGMAR1NAMPT | |
| SCHEMBL5650123 | 0.81 | CSF1R (0.39) | L3MBTL1AKR1C3CSF1RSIGMAR1NAMPT | |
| SCHEMBL5650117 | 0.81 | CSF1R (0.39) | L3MBTL1AKR1C3CSF1RSIGMAR1NAMPT | |
| SCHEMBL4185130 | 0.80 | HTT (0.46) | KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL14405008 | 0.80 | HTT (0.46) | KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL5650248 | 0.80 | HTT (0.46) | KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL8898560 | 0.77 | POLB (0.55) | L3MBTL1POLBKMT2AHPGDTSHR | |
| SCHEMBL1916848 | 0.76 | AKR1C3 (0.60) | AKR1C3POLBKMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452996-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| EP-2021329-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-9221797-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| US-8674100-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-03-18 | — | — | US | disclosed |
| EP-2687516-A1 | Inhibitors of C-FMS Kinase | Janssen Pharmaceutica N.V. (BE) | 2014-01-22 | — | — | EP | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | L3MBTL1 919/4885AKR1C3 4230/4885CSF1R 58/4885 |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | L3MBTL1 919/4885AKR1C3 4230/4885CSF1R 58/4885 |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | L3MBTL1 919/4885AKR1C3 4230/4885CSF1R 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.